13 results
424B3
PRDS
Pardes Biosciences Inc
1 Apr 22
Prospectus supplement
4:01pm
, commercial managed care and medical affairs experience, most recently as Head of Healthcare Delivery Innovation for Genentech, Inc. (a member of the Roche … of Healthcare Delivery Innovation for Genentech, Inc. (a member of the Roche Group). Our Chief Business & Strategy Officer, Philippe Tinmouth, has over
POS AM
PRDS
Pardes Biosciences Inc
30 Mar 22
Prospectus update (post-effective amendment)
7:32am
, commercial managed care and medical affairs experience, most recently as Head of Healthcare Delivery Innovation for Genentech, Inc. (a member … experience, most recently as Head of Healthcare Delivery Innovation for Genentech, Inc. (a member of the Roche Group). Our Chief Business & Strategy
10-K
2021 FY
PRDS
Pardes Biosciences Inc
29 Mar 22
Annual report
5:29pm
affairs experience, most recently as Head of Healthcare Delivery Innovation for Genentech, Inc. (a member of the Roche Group). Our Chief Business … Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug
424B3
PRDS
Pardes Biosciences Inc
1 Feb 22
Prospectus supplement
5:03pm
Delivery Innovation for Genentech, Inc. (a member of the Roche Group). Our Chief Business & Strategy Officer, Philippe Tinmouth, brings over 25 years … , commercial managed care and medical affairs experience, most recently as Head of Healthcare Delivery Innovation for Genentech, Inc. (a member of the Roche
8-K
p1bhqycx i6
30 Dec 21
Entry into a Material Definitive Agreement
4:55pm
425
6ebgsvmeqex7qmmid
5 Aug 21
Business combination disclosure
7:05am
424B4
ciaxibthfln
18 Feb 21
Prospectus supplement with pricing info
4:28pm
S-1
fe7fq27jtk ynaupw
26 Jan 21
IPO registration
4:24pm
DRS
tzqr5v9vh1zt6ot
2 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next